Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis – whom, when and how

References

• Codarri L, Greter M, Becher B. Communication between pathogenic T-cells and myeloid cells in neuroinflammatory disease. Trends Immunol 2013;34:114–19.
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938–52.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606–16.
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938–52.
   PubMed Web of Science ®Google Scholar
• Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999;122:1941–50.
   PubMed Web of Science ®Google Scholar
• Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol 2014;72:1–5.
   PubMed Web of Science ®Google Scholar
• Kasper LH, Shoemaker J. Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 2010 5;74:S2–8.
   Web of Science ®Google Scholar
• Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214–9.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL. Epstein−Barr virus and multiple sclerosis: a review. J Neuroimmune Pharmacol 2010;5:271–7.
   PubMed Web of Science ®Google Scholar
• Hedström AK, Hillert J, Olsson T, et al. Smoking and multiple sclerosis susceptibility. Eur J Epidemiol 2013;28:867–74.
   PubMed Web of Science ®Google Scholar
• Hedström AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012;18:1334–6.
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Brara SM, Beaber BE, et al. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013;80:548–52.
   PubMed Web of Science ®Google Scholar
• Munger KL, Bentzen J, Laursen B, et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler 2013;19:1323–9.
   PubMed Web of Science ®Google Scholar
• Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology 2009;73:1543–50.
   PubMed Web of Science ®Google Scholar
• Matarese G, Procaccini C, De Rosa V. The intricate interface between immune and metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis? J Leukoc Biol 2008;84:893–9.
   PubMed Web of Science ®Google Scholar
• Radaelli M, Merlini A, Greco R, et al. Autologous bone marrow transplantation for the treatment of multiple sclerosis. Curr Neurol Neurosci. 2014;14:478.
   PubMed Web of Science ®Google Scholar
• Comi G. Induction vs escalating therapy in multiple sclerosis: practical implications. Neurol Sci 2008;29 Suppl 2:S253–5.
   PubMed Web of Science ®Google Scholar
• Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol 2005;62: 785–92.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012;47:770–90.
   PubMed Web of Science ®Google Scholar
• Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009;8:244–53.
   PubMed Web of Science ®Google Scholar
• Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005;201:805–16.
   PubMed Web of Science ®Google Scholar
• Darlington PJ, Touil T, Doucet JS, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 2013;73:341–54.
   PubMed Web of Science ®Google Scholar
• Pfender N, Saccardi R, Martin R. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr Treat Options Neurol 2013;15:270–280.
   PubMed Web of Science ®Google Scholar
• Saccardi R, Freedman MS, Sormani MP, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler 2012;18:825–34.
   PubMed Web of Science ®Google Scholar
• Shevchenko JL, Kuznetsov AN, Ionova TI, et al. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives. Ann Hematol 2015;94:1149–57.
   PubMed Web of Science ®Google Scholar
• Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008;7:626–36.
   PubMed Web of Science ®Google Scholar
• Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 2009;15:229–37.
   PubMed Web of Science ®Google Scholar
• Burman J, Iacobaeus E, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 2014;85:1116–21.
   PubMed Web of Science ®Google Scholar
• Burt RK, Cohen BA, Russell E, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003;102:2373–78.
   PubMed Web of Science ®Google Scholar
• Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003;102:2364–72.
   PubMed Web of Science ®Google Scholar
• Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997;20:631–8.
   PubMed Web of Science ®Google Scholar
• Nash RA, Hutton GJ, Racke MK et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol 2015;72:159–69.
   PubMed Web of Science ®Google Scholar
• Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 2015;84:981–8.
   PubMed Web of Science ®Google Scholar